| 2024-11-13 | -0.96 % |
|
| 2024-11-12 | -1.58 % |
|
| 2024-11-08 | +0.71 % |
|
| 2024-11-07 | -1.61 % |
|
| 2024-11-06 | +3.94 % |
|
| 2024-10-31 | -4.73 % |
|
| 2024-10-30 | -0.14 % |
|
| 2024-10-29 | -0.55 % |
|
| 2024-10-28 | +1.36 % |
|
| 2024-10-25 | +1.38 % |
|
| 2024-10-24 | -7.27 % |
|
| 2024-10-23 | |
|
| 2024-10-22 | -1.25 % |
|
| 2024-10-21 | -2.32 % |
|
| 2024-10-18 | +1.2 % |
|
| 2024-10-17 | +0.36 % |
|
| 2024-10-15 | -0.1 % |
|
| 2024-10-14 | +1.73 % |
|
| 2024-10-10 | +0.64 % |
|
| 2024-10-09 | +0.91 % |
|
| 2024-10-08 | +0.6 % |
|
| 2024-10-04 | +1.07 % |
|
| 2024-10-03 | -1.88 % |
|
| 2024-10-01 | -2.36 % |
|
| 2024-09-26 | +1.95 % |
|
| 2024-09-25 | -3.28 % |
|
| 2024-09-24 | -0.48 % |
|
| 2024-09-20 | -1.02 % |
|
| 2024-09-17 | +0.25 % |
|
| 2024-09-04 | +0.01 % |
|
| 2024-09-03 | -1.09 % |
|
| 2024-08-14 | -0.94 % |
|
| 2024-08-05 | -3.36 % |
|
| 2024-08-01 | +0.87 % |
|
| 2024-07-25 | -2.71 % |
|
| 2024-07-24 | -0.02 % |
|
| 2024-07-23 | -2.63 % |
- IQVIA Holdings (NYSE:IQV) stock declined by 2.63% following a mixed financial outlook update from Truist Securities, which, despite raising its price target and adjusted EPS estimates, also lowered its revenue forecasts for Research & Development Solutions.
- IQVIA's stock (IQV) fell by 2.63% after the company reported a modest 2.3% revenue increase in the second quarter of 2024, despite strong performance and growth projections, which may signal investor concern about the company's cautious growth relative to broader expectations or market conditions.
- IQVIA Holdings (NYSE:IQV) stock fell by 2.63% despite Deutsche Bank maintaining a Buy rating and a price target of $275, amidst ongoing investor skepticism regarding projected growth in Technology & Analytics Solutions (TAS) and concerns over client budget constraints and project delays.
- IQVIA Holdings Inc (NYSE:IQV) stock fell by 2.63% despite showcasing strong revenue growth and earnings, which may be attributed to industry-specific risks, regulatory challenges, rising operational costs, and competitive pressures outlined in the recent analysis.
|
| 2024-07-22 | +9.2 % |
|
| 2024-07-19 | -0.12 % |
|
| 2024-07-15 | +0.77 % |
|
| 2024-07-12 | +2.16 % |
|
| 2024-07-11 | +3.52 % |
|
| 2024-07-01 | -1.4 % |
|
| 2024-06-27 | +0.74 % |
|
| 2024-06-26 | -0.11 % |
|
| 2024-06-24 | -1 % |
- The article discusses the upcoming 2024 Fierce Clinical Summit organized by Fierce Pharma, which will cover various topics related to clinical research and trial management, with major sponsors being IQVIA, Advarra, and H1; the reason why IQVIA (IQV) stock was down by -1.0% could be due to various factors such as market conditions, investor sentiment, company performance, or external economic events.
- The article discusses the recent -1.0% drop in IQVIA (IQV) stock and attributes it to the underperformance and lack of investor interest in two newly launched weight-loss exchange-traded funds (ETFs), Roundhill GLP-1 & Weight Loss ETF (OZEM) and Amplify Weight Loss Drug & Treatment ETF (THNR), due to their high expense ratios, concentrated exposure to Eli Lilly (LLY) and Novo Nordisk (NVO), as well as the availability of numerous other weight loss treatment assets in the market.
|
| 2024-06-21 | +0.96 % |
|
| 2024-06-18 | -0.23 % |
|
| 2024-06-14 | -0.57 % |
|
| 2024-06-12 | +0.76 % |
|
| 2024-06-11 | -0.15 % |
|
| 2024-06-10 | -1.55 % |
|
| 2024-06-07 | -0.57 % |
|
| 2024-06-06 | +0.73 % |
|
| 2024-06-05 | +0.79 % |
|
| 2024-06-03 | -1.2 % |
|
| 2024-05-31 | -1.51 % |
- The article discusses Aurobindo Pharma's USFDA approval for Mometasone Furoate Monohydrate Nasal Spray, projected to have a market size of $44.5 million, as per IQVIA data, and the company's overall operations. The decline in IQV stock price could be attributed to various factors, such as market fluctuations, investor sentiment, industry news, or company-specific events.
- The article discusses Veeva Systems Inc.'s fiscal 2025 first-quarter results, highlighting a total revenue of $650 million, non-GAAP operating income of $261 million, and a downward revision of full-year revenue guidance by $30 million to $2.71 billion due to a challenging macroeconomic environment. Veeva's resilience amidst challenges, strong fundamentals such as a significant market capitalization and gross profit margin, and strategic focus on AI applications are emphasized. The company's stock, Veeva (VEEV), generally trades with low price volatility, indicating investor confidence and a potentially lower risk profile. Despite strong performance, Veeva adjusted its revenue outlook, prompting the stock to fall by -1.51% last night, likely influenced by the revised guidance and broader market conditions.
|
| 2024-05-29 | -0.75 % |
|
| 2024-05-24 | +1.11 % |
|
| 2024-05-21 | -0.31 % |
|
